Version history

{
  "description": "The abstract identifies the 'potential' for diagnostic imaging biomarkers but doesn't address validation challenges or clinical implementation. This represents a critical translational gap for moving glymphatic research into clinical practice.\n\nGap type: open_question\nSource paper: Mapping the Brain's Glymphatic System. (2026, Biomedicines, PMID:41751308)",
  "domain": "neurodegeneration",
  "status": "open",
  "priority_score": 0.86,
  "importance_score": 0.88,
  "tractability_score": 0.85,
  "source": "pubmed:41751308",
  "resolution_criteria": "[\"Prospective multi-site study (n>=200 participants with confirmed AD, PD, or FTD) undergoes glymphatic MRI (along perivascular spaces) with standardized aquaporin-4 genotyping\", \"Glymphatic clearance rate (Ktrans from DCE-MRI) discriminates neurodegenerative disease from healthy controls with AUC >= 0.80\", \"Longitudinal data over 24 months shows correlation between baseline glymphatic function and cognitive decline rate\", \"Multivariate model including A\\u03b2 PET, tau PET, and glymphatic MRI improves diagnostic classification vs PET alone\"]",
  "market_price": 0.5
}